Zealand Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

zealandpharma.com

Founded Year

1998

Stage

IPO | IPO

Total Raised

$97.7M

Date of IPO

11/23/2010

Market Cap

0.57B

Stock Price

12.33

About Zealand Pharma

Zealand Pharma is a biotechnology company focused on the discovery, design, and development of peptide-based medicines.

Zealand Pharma Headquarter Location

Smedeland 36 Glostrup

2600,

Denmark

+45 8 877-3600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zealand Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zealand Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Zealand Pharma Patents

Zealand Pharma has filed 111 patents.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Peptide hormones
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/1/2020

6/21/2022

Medical equipment, Drug delivery devices, Dosage forms, Honeycombs (geometry), Copolymers

Grant

Application Date

7/1/2020

Grant Date

6/21/2022

Title

Related Topics

Medical equipment, Drug delivery devices, Dosage forms, Honeycombs (geometry), Copolymers

Status

Grant

Latest Zealand Pharma News

Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design

Jun 21, 2022

Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery June 21, 2022 03:00 AM Eastern Daylight Time PARIS--( BUSINESS WIRE )--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties. Zealand Pharma A/S has a track record of successfully inventing and developing novel peptide-based drugs. This success is based on the extensive experience in improving the therapeutic characteristics of peptides. Zealand Pharma has a keen interest in expanding its computational chemistry toolbox to include AI and machine learning based approaches for the design of novel therapeutic peptides ( https://www.zealandpharma.com/ ). Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI. “We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery” commented Yann Gaston-Mathé, President and CEO of Iktos. “We look forward to working with Zealand’s experienced R&D team to build leading/state of the art peptide generative and predictive modelling technology in the field of peptides - a new area for Iktos.” # # # About IKTOS Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties. More information on: http://www.iktos.ai/

Zealand Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Zealand Pharma Rank

  • When was Zealand Pharma founded?

    Zealand Pharma was founded in 1998.

  • What is Zealand Pharma's latest funding round?

    Zealand Pharma's latest funding round is IPO.

  • How much did Zealand Pharma raise?

    Zealand Pharma raised a total of $97.7M.

  • Who are the investors of Zealand Pharma?

    Investors of Zealand Pharma include AGF Private Equity, Life Sciences Partners, CDC Entreprises, BankInvest Group, LD Fonde and 4 more.

  • Who are Zealand Pharma's competitors?

    Competitors of Zealand Pharma include Tubilux Pharma, OyaGen, Putney, Santaris Pharma, Antisense Pharma and 14 more.

You May Also Like

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

E
Ethos Pharmaceuticals

Developer of novel variants of peptide drugs.

X
Xytis

Xytis is engaged in the development of central nervous systems drugs.

O
OyaGen

OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

K
KeyBay Pharma

KeyBay Pharma is dedicated to the discovery, development and commercialization of antibiotics.

E
Endotis Pharma

Endotis Pharma is A specialty discovery and development company developing small glycol drugs for thrombosis and oncology

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.